{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:12:25Z","timestamp":1789661545354,"version":"4.0.1"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1097\/fpc.0b013e32801a3c10","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T18:55:56Z","timestamp":1236192956000},"page":"339-347","source":"Crossref","is-referenced-by-count":36,"title":["CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6\u2013serotonin\u2013dopamine crosstalk revisited"],"prefix":"10.1097","volume":"17","author":[{"given":"Vural","family":"Ozdemir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Reist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Wid\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Olof","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J.","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Endrenyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kalow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210212","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-5-20210212","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/oxfordjournals.schbul.a006926","article-title":"The Mount Sinai conference on the pharmacotherapy of schizophrenia","volume":"28","author":"Marder","year":"2002","journal-title":"Schizophr Bull"},{"key":"R3-5-20210212","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-200241070-00001","article-title":"Cytochrome p450 phenotyping\/genotyping in patients receiving antipsychotics: useful aid to prescribing?","volume":"41","author":"Dahl","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R4-5-20210212","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/14656566.7.2.119","article-title":"Pharmacogenetics for off-patent antipsychotics: re-defining the risk for tardive dyskinesia and access to essential medicines","volume":"7","author":"Ozdemir","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"R5-5-20210212","first-page":"205","article-title":"The evolving science of pharmacogenetics: clinical and ethnic perspectives","volume":"32","author":"Lin","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"R6-5-20210212","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00004714-198806000-00008","article-title":"Haloperidol and prolactin concentrations in Asians and Caucasians","volume":"8","author":"Lin","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"R7-5-20210212","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1176\/ajp.146.10.1307","article-title":"A longitudinal assessment of haloperidol doses and serum concentrations in Asians and Caucasian schizophrenic patients","volume":"146","author":"Lin","year":"1989","journal-title":"Am J Psychiatry"},{"key":"R8-5-20210212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","article-title":"Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs","volume":"53","author":"Bertilsson","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R9-5-20210212","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrd1801","article-title":"Pharmacogenetics-based therapeutic recommendations: ready for clinical practice?","volume":"4","author":"Kirchheiner","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"R10-5-20210212","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.toxlet.2005.10.015","article-title":"Genetic basis of toxic reactions to drugs and chemicals","volume":"162","author":"Cascorbi","year":"2006","journal-title":"Toxicol Lett"},{"key":"R11-5-20210212","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/clpt.1992.38","article-title":"Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin","volume":"51","author":"Bertilsson","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"R12-5-20210212","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0026-895X(25)09721-4","article-title":"Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation","volume":"46","author":"Johansson","year":"1994","journal-title":"Mol Pharmacol"},{"key":"R13-5-20210212","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0165-6147(91)90516-U","article-title":"Interethnic variation of drug metabolism","volume":"12","author":"Kalow","year":"1991","journal-title":"Trends Pharmacol Sci"},{"key":"R14-5-20210212","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/clpt.1985.81","article-title":"Dissociation of co-regulatory control of debrisoquin\/phenformin and sparteine oxidation in Ghanaians","volume":"37","author":"Woolhouse","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"R15-5-20210212","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.npp.1300919","article-title":"Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochrome P4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients","volume":"31","author":"Suzuki","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R16-5-20210212","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/0929867043456052","article-title":"Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics","volume":"11","author":"Albers","year":"2004","journal-title":"Curr Med Chem"},{"key":"R17-5-20210212","first-page":"327","article-title":"Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia","volume":"31","author":"Pollock","year":"1995","journal-title":"Psychopharmacol Bull"},{"key":"R18-5-20210212","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF00432245","article-title":"Dose\u2013response relationships of perphenazine in the treatment of acute psychosis","volume":"78","author":"Bolvig Hansen","year":"1982","journal-title":"Psychopharmacology"},{"key":"R19-5-20210212","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/schbul\/17.2.197","article-title":"Neuroleptic plasma levels","volume":"17","author":"Van Putten","year":"1991","journal-title":"Schizophr Bull"},{"key":"R20-5-20210212","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0009-9236(97)90037-0","article-title":"Paroxetine potentiates the central nervous system side-effects of perphenazine: contribution of cytochrome P450 2D6 inhibition in vivo","volume":"62","author":"Ozdemir","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"R21-5-20210212","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.1989.109","article-title":"Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings","volume":"46","author":"Dahl-Puustinen","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"R22-5-20210212","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1081\/DMR-120034000","article-title":"Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates","volume":"36","author":"Yu","year":"2004","journal-title":"Drug Metab Rev"},{"key":"R23-5-20210212","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00008571-200303000-00007","article-title":"Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6","volume":"13","author":"Yu","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R24-5-20210212","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/01.fpc.0000167331.30905.9e","article-title":"Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets","volume":"15","author":"Kirchheiner","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R25-5-20210212","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00008571-200104000-00007","article-title":"Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain","volume":"11","author":"Siegle","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R26-5-20210212","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0169-328X(02)00177-8","article-title":"Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain","volume":"103","author":"Chinta","year":"2002","journal-title":"Brain Res Mol Brain Res"},{"key":"R27-5-20210212","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00008571-200306000-00002","article-title":"Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase","volume":"13","author":"Yu","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R28-5-20210212","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/0003-9861(90)90741-G","article-title":"The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins","volume":"276","author":"Niznik","year":"1990","journal-title":"Arch Biochem Biophys"},{"key":"R29-5-20210212","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0026-895X(25)12855-1","article-title":"Neuronal cytochrome P450IID1 (debrisoquine\/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6","volume":"40","author":"Tyndale","year":"1991","journal-title":"Mol Pharmacol"},{"key":"R30-5-20210212","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(89)90094-9","article-title":"Debrisoquine hydroxylation polymorphism and personality","volume":"1","author":"Bertilsson","year":"1989","journal-title":"Lancet"},{"key":"R31-5-20210212","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0447.1993.tb03325.x","article-title":"Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6","volume":"87","author":"Llerena","year":"1993","journal-title":"Acta Psychiatr Scand"},{"key":"R32-5-20210212","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short form health survey (SF-36): conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"R33-5-20210212","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.mp.4001495","article-title":"Inter-relationships of intermediate phenotypes for serotonin function, impulsivity, and a 5-HT2A candidate allele: His452Tyr","volume":"9","author":"Reist","year":"2004","journal-title":"Mol Psychiatry"},{"key":"R34-5-20210212","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/clinchem\/46.1.18","article-title":"Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population","volume":"46","author":"Garcia-Barcelo","year":"2000","journal-title":"Clin Chem"},{"key":"R35-5-20210212","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-2001-18035","article-title":"Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients","volume":"34","author":"Lam","year":"2001","journal-title":"Pharmacopsychiatry"},{"key":"R36-5-20210212","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0009-9236(96)90111-3","article-title":"The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol","volume":"59","author":"Jerling","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"R37-5-20210212","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-9236(96)90165-4","article-title":"Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism","volume":"60","author":"Linnet","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"R38-5-20210212","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00004714-200004000-00010","article-title":"Pharmacologic profile of perphenazine's metabolites","volume":"20","author":"Sweet","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R39-5-20210212","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2125.2000.00298.x","article-title":"Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine","volume":"50","author":"Olesen","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"R40-5-20210212","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0006-2952(74)90421-3","article-title":"Metabolism of trifluoperazine, fluphenazine, prochlorperazine and perphenazine in rats: in vitro and urinary metabolites","volume":"23","author":"Gaertner","year":"1974","journal-title":"Biochem Pharmacol"},{"key":"R41-5-20210212","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00403866","article-title":"Urinary excretion of perphenazine and its sulfoxide during administration in oral and long-acting injectable form","volume":"21","author":"Van Kempen","year":"1971","journal-title":"Psychopharmacologia (Berlin)"},{"key":"R42-5-20210212","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/archpsyc.1964.01720240093010","article-title":"Perphenazine (Trilafon) metabolism in psychotic patients","volume":"10","author":"Li Huang","year":"1963","journal-title":"Arch Gen Psychiatry"},{"key":"R43-5-20210212","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00213-004-1802-1","article-title":"A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration","volume":"175","author":"Talvik","year":"2004","journal-title":"Psychopharmacology (Berlin)"},{"key":"R44-5-20210212","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0140-6736(77)91430-1","article-title":"Polymorphic hydroxylation of debrisoquine in man","volume":"2","author":"Mahgoub","year":"1977","journal-title":"Lancet"},{"key":"R45-5-20210212","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00562059","article-title":"Defective N-oxidation of sparteine in man: a new pharmacogenetic defect","volume":"16","author":"Eichelbaum","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"R46-5-20210212","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004850-199200710-00001","article-title":"Impulsive aggression and central serotonergic system function in humans: an example of a dimensional brain-behavior relationship","volume":"7","author":"Coccaro","year":"1992","journal-title":"Int Clin Psychopharmacol"},{"key":"R47-5-20210212","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ajmg.b.20063","article-title":"A psychometrically derived impulsive trait related to a polymorphism in the serotonin transporter gene-linked polymorphic region (5-HTTLPR) in a Japanese nonclinical population: assessment by the Barratt impulsiveness scale (BIS)","volume":"121","author":"Sakado","year":"2003","journal-title":"Am J Med Genet B: Neuropsychiatr Genet"},{"key":"R48-5-20210212","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajmg.b.20163","article-title":"Association between cytochrome P450 2D6 genotype and harm avoidance","volume":"127","author":"Roberts","year":"2004","journal-title":"Am J Med Genet B: Neuropsychiatr Genet"},{"key":"R49-5-20210212","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1365-2125.2004.02076.x","article-title":"Relationship between type A and B personality and debrisoquine hydroxylation capacity","volume":"57","author":"Gan","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R50-5-20210212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.ypg.0000056175.32550.37","article-title":"Cytochrome P450 2D6 polymorphism and character traits","volume":"13","author":"Suzuki","year":"2003","journal-title":"Psychiatr Genet"},{"key":"R51-5-20210212","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.jcp.0000229484.52955.22","article-title":"Association of CYP2D6 genotypes and personality traits in healthy individuals","volume":"26","author":"Kirchheiner","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R52-5-20210212","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0006-2952(97)00516-9","article-title":"Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain","volume":"55","author":"McFayden","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"R53-5-20210212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF01249284","article-title":"Concentration of 5-methoxyindoles in the human pineal gland","volume":"54","author":"Beck","year":"1982","journal-title":"J Neural Transm"},{"key":"R54-5-20210212","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF01249192","article-title":"Seasonal variations in HIOMT activity during the night in the pineal gland of 21 day old male Wistar rats","volume":"49","author":"Balemans","year":"1980","journal-title":"J Neural Transm"},{"key":"R55-5-20210212","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1111\/j.1471-4159.1981.tb10827.x","article-title":"In vivo formation of 5-methoxytryptamine from melatonin in rat","volume":"36","author":"Beck","year":"1981","journal-title":"J Neurochem"},{"key":"R56-5-20210212","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004714-199708000-00009","article-title":"The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status","volume":"17","author":"Spigset","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"R57-5-20210212","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s002139900364","article-title":"Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene","volume":"149","author":"Mihara","year":"2000","journal-title":"Psychopharmacology (Berlin)"},{"key":"R58-5-20210212","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00008571-199704000-00001","article-title":"Tryptamine: a possible endogenous substrate for CYP2D6","volume":"7","author":"Martinez","year":"1997","journal-title":"Pharmacogenetics"},{"key":"R59-5-20210212","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1124\/jpet.102.043786","article-title":"The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine","volume":"304","author":"Yu","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R60-5-20210212","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1006\/bbrc.1998.9232","article-title":"Dopamine formation from tyramine by CYP2D6","volume":"249","author":"Hiroi","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"R61-5-20210212","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00008571-200306000-00001","article-title":"In search of endogenous CYP2D6 substrates","volume":"13","author":"Eichelbaum","year":"2003","journal-title":"Pharmacogenetics"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/01213011-200705000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:22:44Z","timestamp":1738974164000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-200705000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e32801a3c10","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}